BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17047487)

  • 1. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity.
    Carmo H; Brulport M; Hermes M; Oesch F; Silva R; Ferreira LM; Branco PS; Boer Dd; Remião F; Carvalho F; Schön MR; Krebsfaenger N; Doehmer J; Bastos Mde L; Hengstler JG
    Pharmacogenet Genomics; 2006 Nov; 16(11):789-99. PubMed ID: 17047487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA).
    Carmo H; Brulport M; Hermes M; Oesch F; de Boer D; Remião F; Carvalho F; Schön MR; Krebsfaenger N; Doehmer J; Bastos Mde L; Hengstler JG
    Toxicology; 2007 Jan; 229(3):236-44. PubMed ID: 17156908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
    Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells.
    Carvalho M; Hawksworth G; Milhazes N; Borges F; Monks TJ; Fernandes E; Carvalho F; Bastos ML
    Arch Toxicol; 2002 Oct; 76(10):581-8. PubMed ID: 12373454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity mechanisms of thioether ecstasy metabolites.
    Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
    Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
    Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
    Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolites of ecstasy and cytotoxicity effects].
    Fleury MB; Neudörffer A; Felim A; Blanco M; Monnet FP; Largeron M
    Ann Pharm Fr; 2009 Mar; 67(2):91-6. PubMed ID: 19298892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity.
    Antolino-Lobo I; Meulenbelt J; Nijmeijer SM; Scherpenisse P; van den Berg M; van Duursen MB
    Drug Metab Dispos; 2010 Jul; 38(7):1105-12. PubMed ID: 20388857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial plate assays and electrochemical methods: an efficient tandem for evaluating the ability of catechol-thioether metabolites of MDMA ("ecstasy") to induce toxic effects through redox-cycling.
    Felim A; Urios A; Neudörffer A; Herrera G; Blanco M; Largeron M
    Chem Res Toxicol; 2007 Apr; 20(4):685-93. PubMed ID: 17355154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
    Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia.
    Capela JP; Meisel A; Abreu AR; Branco PS; Ferreira LM; Lobo AM; Remião F; Bastos ML; Carvalho F
    J Pharmacol Exp Ther; 2006 Jan; 316(1):53-61. PubMed ID: 16183702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
    O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
    J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship.
    Milhazes N; Cunha-Oliveira T; Martins P; Garrido J; Oliveira C; Rego AC; Borges F
    Chem Res Toxicol; 2006 Oct; 19(10):1294-304. PubMed ID: 17040098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro.
    Hayat S; Williams RJ; Rattray M
    J Psychopharmacol; 2006 Mar; 20(2):257-63. PubMed ID: 16510483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
    Fonsart J; Menet MC; Declèves X; Galons H; Crété D; Debray M; Scherrmann JM; Noble F
    Toxicol Appl Pharmacol; 2008 Jul; 230(1):117-25. PubMed ID: 18358511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
    Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6.
    Lin LY; Di Stefano EW; Schmitz DA; Hsu L; Ellis SW; Lennard MS; Tucker GT; Cho AK
    Drug Metab Dispos; 1997 Sep; 25(9):1059-64. PubMed ID: 9311621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
    Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
    Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro.
    Carvalho M; Remião F; Milhazes N; Borges F; Fernandes E; Monteiro Mdo C; Gonçalves MJ; Seabra V; Amado F; Carvalho F; Bastos ML
    Chem Res Toxicol; 2004 May; 17(5):623-32. PubMed ID: 15144219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT.
    Aitchison KJ; Tsapakis EM; Huezo-Diaz P; Kerwin RW; Forsling ML; Wolff K
    J Psychopharmacol; 2012 Mar; 26(3):408-18. PubMed ID: 22303032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.